Eugene P. Harper

Eugene P. Harper

Auto-generated profile, based on publicly available information

Eugene P. Harper

Department of Internal Medicine, Mayo Clinic, Jacksonville, FL

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2017 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JOJohn C O’horo
John C O’horo
EHEugene P Harper
Eugene P Harper
ARAbdelghani El Rafei
Abdelghani El Rafei
RARashid Ali
Rashid Ali
DDDaniel C DeSimone
Daniel C DeSimone
PTPritish K Tosh
Pritish K Tosh
Botulism is a rare, potentially severe illness, often fatal if not appropriately treated. Data on treatment are sparse. We systematically evaluated the literature on botulinum antitoxin and other treatments. We conducted a systematic literature review of published articles in PubMed via Medline, Web of Science, Embase, Ovid, and Cumulative Index to Nursing and Allied Health Literature, and included all studies that reported on the clinical course and treatment for foodborne botulism. Articles were reviewed by 2 independent reviewers and independently abstracted for treatment type and toxin exposure. We conducted a meta-analysis on the effect of timing of antitoxin administration, antitoxin type, and toxin exposure type. We identified 235 articles that met the inclusion criteria, published between 1923 and 2016. Study quality was variable. Few (27%) case series reported sufficient data for inclusion in meta-analysis. Reduced mortality was associated with any antitoxin treatment (odds ratio [OR], 0.16; 95% confidence interval [CI], .09–.30) and antitoxin treatment within 48 hours of illness onset (OR, 0.12; 95% CI, .03–.41). Data did not allow assessment of critical care impact, including ventilator support, on survival. Therapeutic agents other than antitoxin offered no clear benefit. Patient characteristics did not predict poor outcomes. We did not identify an interval beyond which antitoxin was not beneficial. Published studies on botulism treatment are relatively sparse and of low quality. Timely administration of antitoxin reduces mortality; despite appropriate treatment with antitoxin, some patients suffer respiratory failure. Prompt antitoxin administration and meticulous intensive care are essential for optimal outcome.

1 March 2017 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
TCThomas G. Cotter
Thomas G. Cotter
MBMoritz Binder
Moritz Binder
EHEugene P. Harper
Eugene P. Harper
TSThomas C. Smyrk
Thomas C. Smyrk
DPDarrell S. Pardi
Darrell S. Pardi
Goals: Our aim was to develop a scoring system to predict risk of microscopic colitis (MC), to identify patients at low risk, potentially avoiding unnecessary biopsies. Background: Patients with chronic diarrhea often undergo colonoscopy with biopsy, but few have histologic abnormalities. Study: We conducted a retrospective study of patients with chronic diarrhea and a macroscopically normal colonoscopy at our institution over a 9-month period. Multivariable logistic regression assessed the association between predictors and the presence of biopsy-proven MC. Results: The derivation cohort included 617 patients. Median age was 55.1 (39.6 to 68.1) years; 397 (64.3%) were female and 81 (13.1%) had MC. Age ≥55 years, duration of diarrhea ≤6 months, ≥5 bowel movements per day, body mass index <30 kg/m2, current smoking, and current use of selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitorss and non-steroidal anti-inflammatory drugs were independently associated with MC. A score of ≥10 points in our scoring system, yielded an area under the ROC curve (AUC) of 0.83 with a sensitivity of 93% and specificity of 49% in predicting which patients have MC. The negative predictive value (NPV) was 97.8% (95.0% to 99.1%). In the validation cohort, the scoring system performed similarly (AUC 0.79, sensitivity 91%, specificity 49%, NPV 97%). By avoiding biopsies in patients at low risk of having MC, costs associated with colon biopsies could be reduced by almost 43%. Conclusion: This scoring system including 7 clinical variables was able to identify patients unlikely to have MC, with excellent sensitivity, reasonable specificity, and a high NPV, translating into important potential cost savings.

10 November 2021 in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Verified
Journal Article
Open access
HZHimesh Zaver
Himesh Zaver
VMVarun P. Moktan
Varun P. Moktan
EHEugene P. Harper
Eugene P. Harper
ABAman Bali
Aman Bali
ANAyan Nasir
Ayan Nasir
WBWendelyn Bosch
Wendelyn Bosch
To reduce health care facility–onset (HCFO) Clostridioides difficile infection (CDI) incidence by improving diagnostic stewardship and reducing the inappropriate testing of C difficile assays. A multidisciplinary team conducted a quality improvement initiative from January 1, 2020, through March 31, 2021. Clostridioides difficile infection and inappropriate testing were identified via electronic health records using predefined criteria related to stool quantity/caliber, confounding medications, and laboratory data. An intervention bundle was designed including (1) provider education, (2) implementation of an appropriate testing algorithm, (3) expert review of C difficile orders, and (4) batch testing of assays to facilitate review and cancellation if inappropriate. Compared with a baseline period from January to September 2020, implementation of our intervention bundle from December 2020 to March 2021 resulted in an 83.6% reduction in inappropriate orders tested and a 41.7% reduction in HCFO CDI incidence. A novel prevention bundle improved C difficile diagnostic stewardship and HCFO CDI incidence by reducing testing of inappropriate orders. Such initiatives targeting HCFO CDI may positively affect patient safety and hospital reimbursement.

1 October 2020 in Mayo Clinic Proceedings
Verified
Journal Article
Open access
PDF file
SESamantha M. Espinosa
Samantha M. Espinosa
EHEugene P. Harper
Eugene P. Harper
MPMichael B. Phillips
Michael B. Phillips
A 19-year-old man with no significant past medical history presented to the emergency department for symptoms of fevers, cough, abdominal pain, nausea, and vomiting. He reported having cyclical fevers up to 103°F for the past week. Four days before presentation, he developed nonlocalized abdominal pain and episodes of nonbloody emesis, not associated with any specific foods. He did not have diarrhea or constipation, and was passing flatus. He also developed a dry cough. Emesis was not associated with coughing fits. He denied having any known sick contacts or any recent travel. The patient endorsed smoking marijuana, as well as vaping, multiple times per week for several months, including tetrahydrocannabinol (THC)–containing vaping solutions. He denied any alcohol or other illicit drug use. He had unprotected sexual intercourse with one partner in the preceding months, but neither had a known history of sexually transmitted infections. He was also up to date on immunizations. Exposures included working on home renovation projects and demolition with his father in the past, but not recently. He had no pertinent past medical history or family history, and took no medications or supplements regularly.

1 June 2021 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
EHEugene P. Harper
Eugene P. Harper
SESamantha M. Espinosa
Samantha M. Espinosa
PVPriyanka Vijapura
Priyanka Vijapura

1 April 2016 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
TCThomas G. Cotter
Thomas G. Cotter
MBMoritz Binder
Moritz Binder
TSThomas Smyrk
Thomas Smyrk
EHEugene P. Harper
Eugene P. Harper
DPDarrell Pardi
Darrell Pardi